earnings
confidence high
sentiment neutral
materiality 0.50
aTyr Pharma Q2 2022 cash $89.3M; initiates Phase 3 sarcoidosis study
aTYR PHARMA INC
2022-Q2 EPS reported
-$0.88
- Cash, restricted cash, cash equivalents and investments $89.3M as of June 30, 2022.
- R&D expenses $9.1M, G&A expenses $3.4M for Q2 2022; no revenue reported.
- First sites initiated in global Phase 3 EFZO-FIT study for pulmonary sarcoidosis.
- FDA Fast Track designation granted for efzofitimod in pulmonary sarcoidosis.
- Company on track to enroll first patient in Q3 2022; 28.1M shares outstanding.